Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

PURPOSE: Lenalidomide is an immunomodulatory drug active as salvage therapy for chronic lymphocytic leukemia (CLL). We combined lenalidomide with rituximab to improve response rates in patients with relapsed or refractory CLL. PATIENTS AND METHODS: Fifty-nine adult patients (age 42 to 82 years) with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Oncol
Hauptverfasser: Badoux, Xavier C., Keating, Michael J., Wen, Sijin, Wierda, William G., O'Brien, Susan M., Faderl, Stefan, Sargent, Rachel, Burger, Jan A., Ferrajoli, Alessandra
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2013
Schlagworte:
ORIGINAL REPORTS
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878047/
https://ncbi.nlm.nih.gov/pubmed/23270003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.42.8623
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge